Jazz Pharmaceuticals Inc

Type: Company
Name: Jazz Pharmaceuticals Inc
First reported Jul 21 2014 - Updated 17 hours ago - 6 reports

Jazz Pharmaceuticals/Concert Pharmaceuticals Start Study

Jazz Pharmaceuticals ( JAZZ ) and partner Concert Pharmaceuticals, Inc. ( CNCE ) announced the initiation of a phase I study (n=28) on JZP-386, a deuterated version of sodium oxybate (the active ingredient in Xyrem). Xyrem is marketed by Jazz Pharma in ... [Published Yahoo! Finance - 17 hours ago]
First reported 18 hours ago - Updated 18 hours ago - 2 reports

Jazz Pharmaceuticals to Report 2014 Second Quarter Financial Results on August 5, 2014

/PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2014 second quarter financial results on Tuesday, August 5, 2014, after the close of the financial markets. Company management will host a live audio webcast ... [Published TickerTech.com - 18 hours ago]
First reported Jul 22 2014 - Updated 23 hours ago - 1 reports

Jazz Pharmaceuticals (JAZZ) Showing Bullish Technicals

A covered call identified by MarketIntelligececenter.com's patented algorithms on Jazz Pharmaceuticals Inc. (JAZZ) could yield about 6.53% (39.73% annualized, for comparison purposes only) in 60 days. Pair a long position in the stock with the Sep. '14 ... [Published MarketIntelligenceCenter.com - Jul 22 2014]
First reported Jul 19 2014 - Updated Jul 19 2014 - 1 reports

Patent Issued for Method for Administering Omega-Conopeptide

By a News Reporter-Staff News Editor at Biotech Week -- A patent by the inventors Ellis, David J. (Los Altos, CA); Miljanich, George P. (Redwood City, CA); Shields, David E. (San Lorenzo, CA), filed on December 18, 2013, was published online on July 1, ... [Published HighBeam Research - Jul 19 2014]
First reported Jul 18 2014 - Updated Jul 18 2014 - 1 reports

Jazz Pharmaceuticals (JAZZ) Showing Support Near $137.86

Jazz Pharmaceuticals Inc. (JAZZ) presents a trading opportunity that offers a 6.91% return in just 64 days.A covered call on Jazz Pharmaceuticals at the $140.00 level expiring on Sep. '14 offers an assigned return rate of 6.91% or 39.41% annualized. This ... [Published MarketIntelligenceCenter.com - Jul 18 2014]
First reported Jul 11 2014 - Updated Jul 11 2014 - 1 reports

Stock Investors Sell Off Shares of Jazz Pharmaceuticals, Down 1.8%

Jazz Pharmaceuticals (NASDAQ:JAZZ) is one of today's biggest movers, down 1.8% to $149.82. The Dow Jones Industrial Average is now trading fractionally lower to 16,904 and the S&P is trading fractionally lower to 1,964. ... [Published Individual.com - Jul 11 2014]
First reported Jul 10 2014 - Updated Jul 10 2014 - 1 reports

Jazz Pharmaceuticals (JAZZ) Trading Near $160.25 Resistance Level

Jazz Pharmaceuticals Inc. (http://www.marketintelligencecenter.com/symbol/JAZZ"JAZZ) was selected by MarketIntelligenceCenter.comaEUR(TM)s trade-picking algorithms today after trading between $150.92 and $156.97 on Wednesday before closing at $154.70. ... [Published Individual.com - Jul 10 2014]
First reported Jul 08 2014 - Updated Jul 08 2014 - 2 reports

Critical Alerts For GoPro, Canadian Solar, Questcor Pharmaceuticals, Caesars

Entertainment, and Jazz Pharmaceuticals Released By InvestorsObserver07/08 08:31 CDT Entertainment, and Jazz Pharmaceuticals Released By InvestorsObserver CHICAGO, July 8, 2014CHICAGO, July 8, 2014 /PRNewswire/ -- InvestorsObserver issues critical ... [Published Finwin - Jul 08 2014]
First reported Jul 07 2014 - Updated Jul 08 2014 - 2 reports

Jazz Pharmaceuticals acquires rights to hepatic VOD drug from Sigma-Tau in US

Jazz Pharmaceuticals plc, a biopharmaceutical company, has signed a definitive agreement with Sigma-Tau Pharmaceuticals, Inc. under which a subsidiary of Jazz will acquire the rights to defibrotide, which is used to treat severe hepatic veno-occlusive ... [Published Individual.com - Jul 08 2014]
First reported Jul 07 2014 - Updated Jul 07 2014 - 1 reports

Jazz Pharmaceuticals (JAZZ) Showing Support Near $158.09

A covered call identified by MarketIntelligececenter.com's patented algorithms on Jazz Pharmaceuticals Inc. (JAZZ) could yield about 6.87% (33.42% annualized, for comparison purposes only) in 75 days. Pair a long position in the stock with the Sep. '14 ... [Published MarketIntelligenceCenter.com - Jul 07 2014]
First reported Jul 03 2014 - Updated Jul 03 2014 - 2 reports

Jazz Pharmaceuticals Public Limited Company (JAZZ)...

Jazz Pharmaceuticals Public Limited Company ( JAZZ ) was a big mover last session, as the company saw its shares rise nearly 7% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This breaks the ... [Published Nasdaq - Jul 03 2014]
First reported Jul 02 2014 - Updated Jul 03 2014 - 7 reports

Jazz Pharma to acquire rights to defibrotide from Sigma-Tau

Jazz Pharmaceuticals (JAZZ) has signed a definitive agreement with Sigma-Tau Pharmaceuticals (Sigma-Tau) under which a subsidiary of Jazz Pharmaceuticals (Jazz) will acquire from Sigma-Tau rights to defibrotide in the United States (US) and all other ... [Published PBR - News - Jul 03 2014]

Quotes

"Initiating this first-in-human Phase 1 study with JZP-386 is an important milestone in our development program and will provide valuable information on the potential benefit of this deuterium-containing analog of sodium oxybate. This study reflects our ongoing commitment to addressing the unmet medical needs of patients with narcolepsy and to further advancing our understanding of sodium oxybate." said Jeffrey Tobias, M D , executive vice president and chief medical officer of Jazz Pharmaceuticals
The profile noted that Ms. Jackson's practice has "evolved over the years to encompass much of the world" citing her recent defense of PAE Government Services in a case involving alleged sexual harassment, race discrimination, and retaliation during the...
The following quote was obtained by the news editors from the background information supplied by the inventors: "In general, although brain pathways governing the perception of pain are still not completely understood, sensory afferent synaptic connections to the spinal cord, termed 'nociceptive pathways' have been documented in some detail. In the first part of such pathways, C- and A-fibers which project from peripheral sites to the spinal cord carry nociceptive signals. Polysynaptic junctions in the dorsal horn of the spinal cord are involved in the relay and modulation of sensations of pain to various regions of the brain, including the periaqueductal grey region (.mu.geer, P L , Eccles, J C , and .mu.geer, E G (1987). Molecular Neurobiology of the Mammalian Brain, Plenum Press, New York). Analgesia, or the reduction of pain perception, can be effected directly by decreasing transmission along such nociceptive pathways. …"
Jazz Pharmaceuticals Inc. (http://www.marketintelligencecenter.com/symbol/JAZZ "JAZZ) was selected by MarketIntelligenceCenter.comaEUR(TM)s trade-picking algorithms today after trading between $150.92 and $156.97 on Wednesday before closing at $154.70. A diagonal spread using a long position in the Jan. '15 $100.00 call and a short position in the $150.00 Sep. '14 call for a net debit of about $44.95 would yield 11.23% in just 72 days. A less risky, but more expensive strategy would be a covered call using the same sold option. Technical indicators for the stock have been bullish and support has been near $148.15 with resistance around $16"

More Content

All (197) | News (87) | Reports (0) | Blogs (98) | Audio/Video (0) | Fact Sheets (0) | Press Releases (11)
sort by: Date | Relevance
Potential Jazz Pharmaceuticals (JAZZ) Trade Has... [Published MarketIntelligenceCenter.com - 2 hours ago]
Jazz Pharmaceuticals plc – Now Covered by Analy... [Published American Banking News - Stock Ratings - 17 hours ago]
Jazz Pharmaceuticals/Concert Pharmaceuticals St... [Published Yahoo! Finance - 17 hours ago]
Jazz Pharmaceuticals to Report 2014 Second Quar... [Published TickerTech.com - 18 hours ago]
Jazz Pharmaceuticals to Report 2014 Second Quar... [Published PR Newswire: Health - 18 hours ago]
Jazz Pharmaceuticals (JAZZ) Showing Bullish Tec... [Published MarketIntelligenceCenter.com - Jul 22 2014]
Jazz Pharmaceuticals and Concert Pharmaceutical... [Published Nasdaq - Jul 21 2014]
Jazz Pharmaceuticals and Concert Pharmaceutical... [Published Investor's Business Daily - Jul 21 2014]
Jazz Pharmaceuticals and Concert Pharmaceutical... [Published Business Wire Photo/Multimedia News - Jul 21 2014]
Jazz Pharmaceuticals and Concert Pharmaceutical... [Published Business Wire Health News - Jul 21 2014]
Jazz Pharmaceuticals and Concert Pharmaceutical... [Published Business Wire News with Multimedia - Jul 21 2014]
Your Best Wealth-Building Choice From Today's T... [Published Seeking Alpha - Jul 21 2014]
Jazz Pharmaceuticals (JAZZ) Trading Near $138.0... [Published MarketIntelligenceCenter.com - Jul 21 2014]
Eandi and Jackson Named Top Labor & Employment ... [Published Baker & McKenzie - Jul 21 2014]
Can Anything Stop Drug Companies From Fleeing T... [Published Forbes.com - Jul 19 2014]
Patent Issued for Method for Administering Omeg... [Published HighBeam Research - Jul 19 2014]
America Just Lost Another Billion-Dollar Compan... [Published Business Insider - Jul 18 2014]
America Just Lost Another Billion-Dollar Compan... [Published Clusterstock - Jul 18 2014]
Jazz Pharmaceuticals (JAZZ) Showing Support Nea... [Published MarketIntelligenceCenter.com - Jul 18 2014]
Jazz Pharmaceuticals (JAZZ) Trading Near $152.7... [Published MarketIntelligenceCenter.com - Jul 17 2014]
Does Yellen Use Technical Analysis? [Published Forbes.com - Jul 16 2014]
Jazz Pharmaceuticals (JAZZ) Trading Near $158.2... [Published MarketIntelligenceCenter.com - Jul 16 2014]
Jazz Pharmaceuticals (JAZZ) Showing Bullish Tec... [Published MarketIntelligenceCenter.com - Jul 15 2014]
Potential Jazz Pharmaceuticals (JAZZ) Trade Has... [Published MarketIntelligenceCenter.com - Jul 14 2014]
Will Earnings Season Provide The Next Catalyst ... [Published Seeking Alpha - Jul 14 2014]
Stock Investors Sell Off Shares of Jazz Pharmac... [Published Individual.com - Jul 11 2014]
Jazz Pharmaceuticals (JAZZ) Showing Bullish Tec... [Published MarketIntelligenceCenter.com - Jul 11 2014]
Jazz Pharmaceuticals (JAZZ) Trading Near $160.2... [Published Individual.com - Jul 10 2014]
The Zacks Analyst Blog Highlights:Regado Biosci... [Published Financial Services - Jul 10 2014]
The Zacks Analyst Blog Highlights: Regado Biosc... [Published Yahoo! Finance - Jul 10 2014]
1 2 3 4 5 6 7
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Potential Jazz Pharmaceuticals (JAZZ) Trade Has... [Published MarketIntelligenceCenter.com - 2 hours ago]
A covered call identified by MarketIntelligececenter.com's patented algorithm on Jazz Pharmaceuticals Inc. (JAZZ) could yield about 7.27% (44.99% annualized, for comparison purposes only) in 59 days. Pair a long position in the stock with the Sep. '14 ...
Jazz Pharmaceuticals to Report 2014 Second Quar... [Published PR Newswire: Health - 18 hours ago]
DUBLIN, July 22, 2014 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2014 second quarter financial results on Tuesday, August 5, 2014, after the close of the financial markets.  Company management will ...
Jazz Pharmaceuticals (JAZZ) Showing Bullish Tec... [Published MarketIntelligenceCenter.com - Jul 22 2014]
A covered call identified by MarketIntelligececenter.com's patented algorithms on Jazz Pharmaceuticals Inc. (JAZZ) could yield about 6.53% (39.73% annualized, for comparison purposes only) in 60 days. Pair a long position in the stock with the Sep. '14 ...
Jazz Pharmaceuticals and Concert Pharmaceutical... [Published Business Wire Photo/Multimedia News - Jul 21 2014]
DUBLIN & LEXINGTON, Mass.--(BUSINESS WIRE)--Jazz Pharmaceuticals and Concert Pharmaceuticals initiated a first-in-human Phase 1 study with JZP-386. ...
Jazz Pharmaceuticals and Concert Pharmaceutical... [Published Business Wire Health News - Jul 21 2014]
DUBLIN & LEXINGTON, Mass.--(BUSINESS WIRE)--Jazz Pharmaceuticals and Concert Pharmaceuticals initiated a first-in-human Phase 1 study with JZP-386. ...
1 2 3 4 5 6 7 8 9 10 ...

Press Releases

sort by: Date | Relevance
The Zacks Analyst Blog Highlights:Regado Biosci... [Published Financial Services - Jul 10 2014]
Agreements, NDA Submissions, FDA Approvals, Enr... [Published Financial Services - Jul 07 2014]
Jazz Pharmaceuticals Announces Agreement To Acq... [Published Financial Services - Jul 02 2014]
Pharmaceuticals Stocks Technical Momentum -- Re... [Published Financial Services - Jun 16 2014]
Appointment, Investor Conferences, and Expanded... [Published Financial Services - May 28 2014]
1 2 3
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.